CIZ1B takes a focused biomarker approach to early lung cancer detection by identifying a specific protein signal produced by lung cancer cells. Learn how this targeted strategy differs from DNA-based cancer blood tests and why earlier detection matters.

Lung cancer screening rates remain dangerously low, with fewer than one in five eligible adults getting screened. New national studies show how many lives could be saved through expanded screening and more accessible tools such as the CIZ1B biomarker blood test. This article breaks down the latest data and why early detection solutions are urgently needed.

While smoking remains the leading cause of lung cancer, tens of thousands of people who have never smoked are diagnosed each year. Learn about other risk factors—like radon, air pollution, and genetics—and how early detection can save lives.